Asset profile
Hydroxyurea (Siklos)
Unknown / undisclosed
Evidence outlook
Approved: Sickle Cell Disease
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Competitive landscape
16 competitors in this universe: 0 direct rivals (same mechanism and indication), 0 same-class, 16 same-indication.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Hydroxyurea (Siklos): this drug | Approved | — | — | ||
| Crizanlizumab-Tmca (Adakveo) | Approved | Monoclonal antibody | P-selectin | ||
| Exagamglogene Autotemcel (Casgevy) | Approved | Gene therapy / editing | — | ||
| Hydroxyurea (Droxia) | Approved | — | — | ||
| Hydroxyurea (Xromi) | Approved | — | — | ||
| L-Glutamine (Endari) | Approved | — | Amino Acid | ||
| Lovotibeglogene Autotemcel (Lyfgenia) | Approved | Gene therapy / editing | — | ||
| Mitapivat (Pyrukynd) | Approved | — | — | ||
| Voxelotor (Oxbryta) | Approved | — | — | ||
| Senicapoc | Phase 3 | — | — | ||
| Decitabine / Tetrahydrouridine (NDec) | Phase 2 | — | DNMT1 (DNA methyltransferase 1) | ||
| HBI-002 | Phase 2 | Small molecule | Carbon monoxide (CO)-based gas therapeutic; oral liquid CO formulation | ||
| ITU512 | Phase 1/2 | — | — | ||
| Nula-Cel | Phase 1/2 | Cell therapy | — | ||
| DISC-3405 | Phase 1 | — | — | ||
| SCD-101 | Phase 1 | — | — |
…and 1 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Upcoming events
(3 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2028 (1)
February 2028 (1)
What to watch
2029 (1)
June 2029 (1)
What to watch
2030 (1)
November 2030 (1)
What to watch
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.